Michela Cortesi
Overview
Explore the profile of Michela Cortesi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Zamagni A, Cortesi M, Zanoni M, Tesei A
Front Chem
. 2019 Oct;
7:651.
PMID: 31616657
Despite the key role played by androgen receptor (AR) in tumor cell aggressiveness and prostate cancer (PCa) progression, its function in the tumor microenvironment (TME) is still controversial. Increasing studies...
22.
Zanoni M, Cortesi M, Zamagni A, Tesei A
Int J Mol Sci
. 2019 Aug;
20(16).
PMID: 31398940
Radiation therapy is one of the most important treatment modalities for thoracic tumors. Despite significant advances in radiation techniques, radiation-induced lung injury (RILI) still occurs in up to 30% of...
23.
Tesei A, Cortesi M, Pignatta S, Arienti C, Dondio G, Bigogno C, et al.
Front Pharmacol
. 2019 Jun;
10:490.
PMID: 31156430
Pancreatic cancer (PC) is one of the most lethal tumor worldwide, with no prognosis improvement over the past 20-years. The silent progressive nature of this neoplasia hampers the early diagnosis,...
24.
Tesei A, Cortesi M, Zamagni A, Arienti C, Pignatta S, Zanoni M, et al.
Front Pharmacol
. 2018 Jul;
9:711.
PMID: 30042674
Despite the interest aroused by sigma receptors (SRs) in the area of oncology, their role in tumor biology remains enigmatic. The predominant subcellular localization and main site of activity of...
25.
Arienti C, Pignatta S, Zanoni M, Cortesi M, Zamagni A, Piccinini F, et al.
J Vis Exp
. 2017 Dec;
(130).
PMID: 29286488
The past two decades have seen a shift from cytotoxic drugs to targeted therapy in medical oncology. Although targeted therapeutic agents have shown more impressive clinical efficacy and minimized adverse...
26.
Ferroni C, Pepe A, Kim Y, Lee S, Guerrini A, Parenti M, et al.
J Med Chem
. 2017 Mar;
60(7):3082-3093.
PMID: 28272894
Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently...
27.
Collina S, Bignardi E, Rui M, Rossi D, Gaggeri R, Zamagni A, et al.
Expert Opin Ther Pat
. 2017 Jan;
27(5):565-578.
PMID: 28051882
Although several molecular targets against cancer have been identified, there is a continuous need for new therapeutic strategies. Sigma Receptors (SRs) overexpression has been recently associated with different cancer conditions....
28.
Rui M, Rossi D, Marra A, Paolillo M, Schinelli S, Curti D, et al.
Eur J Med Chem
. 2016 Nov;
124:649-665.
PMID: 27614411
In the early 2000s, the Sigma Receptor (SR) family was identified as potential "druggable" target in cancer treatment. Indeed, high density of SRs was found in breast, lung, and prostate...